MACH7 TECHNOLOGIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.69 AUD | -1.43% |
|
-3.50% | -12.66% |
| 24/04 | Mach7 Technologies Posts 20% Annual Recurring Revenue Increase to AU$22.3 Million for March Quarter | MT |
| 24/04 | Transcript : Mach7 Technologies Limited, Q3 2024 Earnings Call, Apr 24, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 4.73 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.66% | 110M | - | ||
| -3.25% | 15.01B | - | ||
| -38.91% | 2.8B | C- | ||
| -12.68% | 2.45B | - | ||
| -12.18% | 1.46B | - | - | |
| -.--% | 1.12B | - | - | |
| +48.15% | 534M | - | ||
| +14.96% | 245M | C | ||
| -11.27% | 203M | - | - | |
| +3.33% | 187M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- M7T Stock
- Ratings Mach7 Technologies Limited
